Diagnosis of Canine Tumours and the Value of Combined Detection of VEGF, P53, SF and NLRP3 for the Early Diagnosis of Canine Mammary Carcinoma
View abstract on PubMed
Summary
This summary is machine-generated.Early diagnosis of canine mammary tumors is crucial. A combination of four biomarkers, including vascular endothelial growth factor (VEGF) and tumor protein P53 (P53), shows promise for accurate detection in dogs.
Area Of Science
- Veterinary Medicine
- Oncology
- Biomarker Discovery
Background
- Canine mammary tumors are a leading cause of death in dogs.
- Early diagnosis is critical for effective treatment and improved prognosis.
- Current diagnostic methods have limitations in early detection.
Purpose Of The Study
- To evaluate the diagnostic potential of four biomarkers for canine mammary tumors.
- To compare the expression levels of these biomarkers in healthy dogs, dogs with benign tumors, and dogs with malignant tumors.
Main Methods
- RT-qPCR and ELISA were used to measure the expression of VEGF, P53, serum ferritin (SF), and NLRP3.
- Samples were analyzed from healthy dogs, dogs with benign mammary tumors, and dogs with malignant mammary tumors.
- ROC curve analysis was performed to assess diagnostic accuracy.
Main Results
- All four biomarkers (VEGF, P53, SF, NLRP3) showed significantly higher expression in malignant mammary tumors compared to benign tumors and healthy controls.
- Expression trends were consistent in both serum and tissue samples.
- Combined testing of the four markers demonstrated superior diagnostic performance over single marker tests.
Conclusions
- The combination of VEGF, P53, SF, and NLRP3 shows significant potential for the early and accurate diagnosis of canine mammary tumors.
- These findings can aid in clinical diagnosis and the development of novel tumor detection kits for veterinary practice.

